L'intérêt à découvert pour Bruker donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Bruker. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Bruker (NASDAQ:BRKR) Stock, Rapport sur les intérêts à découvert

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Bruker Corp

Bruker Corporation&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brkr#NASDAQ">BRKR</a>) growth is backed by strong sales within its X-Ray and Nano Analytics businesses. Within the PCI division, expanding customer demand for pre-clinical MRI systems is highly encouraging. Meanwhile, the impact of macroeconomic pressure and currency fluctuation is likely to hurt the company&#39;s operational results.
In the past year, this Zacks Rank #3 (Hold) company&#39;s shares have gained 10.4% compared with the industry&#39;s 27.5% growth and the S&amp;P 500 composite&#39;s 34.9% gain.
This renowned medical device company has a market capitalization of $11.77 billion. It has a 2025 earnings growth rate of 17.6%, which is much higher than the industry&#39;s 13.8% growth rate. BRKR&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.1%.
Let&#39;s delve deeper.
<h2>Bruker&#39;s Key Upsides</h2>
Bright Prospects Within Nano Business Segment:&nbsp;The segment caters to a large set of customers, such as academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses that are involved in materials research and life science research analysis. The business is seeing robust revenue growth across its end markets, including academic, government, industrial and semiconductor metrology.&nbsp;
During the first half of 2024, the company&#39;s advanced X-Ray and Nano Analytics businesses delivered strong sales, backed by Nano&#39;s robust revenue growth. Nano&#39;s strong growth is driven by the rising demand in academic and government markets. The Nanostring acquisition is expected to be both strategically and financially beneficial, promising a high return on investment for Bruker.
The Potential of Preclinical Imaging (PCI) Market: Per Grand View Research, the global PCI market was valued at $4.30 billion in 2023 and is likely to witness a CAGR of 4.6% up to 2030. Therefore, this translates into a golden opportunity for Bruker to expand its foothold in the PCI market and earn higher profits from this division.
Bruker offers advanced PCI solutions for a broad spectrum of application fields. Moreover, this division is experiencing increasing customer demand for higher-strength pre-clinical magnetic resonance imaging systems. Earlier this year, Bruker filled a critical gap in its PCI portfolio with the acquisition of Spectral Instruments Imaging LLC, a leader in preclinical in-vivo optical imaging systems.
<h2>Bruker&#39;s Key Downsides</h2>
Unfavorable Currency Movement: Bruker generates a substantial portion of its revenues in the international markets, primarily in Germany and other countries in the European Union, Switzerland and Japan.&nbsp; As a result, currency fluctuations continue to result in foreign currency transaction losses for the company. In addition, currency fluctuations are likely to cause the price of Bruker&#39;s products to be less competitive than its principal competitors&#39; offerings.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6e/80173.jpg?v=35874249" />
Image Source: Zacks Investment Research
Macroeconomic Factors:&nbsp;Present global economic challenges and uncertainties have made it harder for Bruker to manage operations and predict financial outcomes. Geopolitical conditions are impacting its operational results. In addition, supply-chain risks also persist. All these issues are leading to higher costs and expenditures for the company, impacting its profitability.
In the second quarter, Bruker&#39;s cost of revenues increased 21.6% from the same period in 2023. SG&amp;A expenses surged 24.4%.
<h2>BRKR&#39;s Estimate Trend</h2>
The Zacks Consensus Estimate for Bruker&#39;s 2024 earnings per share remained unchanged at $2.61 for the past 30 days.
The consensus estimate for the company&#39;s 2024 revenues is pegged at $3.41 billion, indicating a 14.9% rise from the year-ago &nbsp;number.
<h2>Key Picks</h2>
Some better-ranked stocks in the broader medical space are&nbsp;TransMedix Group&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>),&nbsp;AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and Phibro Animal Health (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pahc#NASDAQ">PAHC</a>).
TransMedix Group&#39;s earnings are expected to surge 255.8% in 2024. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 287.5%. Shares of the company have risen 173.5% in the past year compared with the industry&#39;s 22.4% growth. TMDX sports a Zacks Rank #1 (Strong Buy) at present.
AxoGen, carrying a Zacks Rank #2 (Buy) at present, has an earning yield of 94.1% compared with the industry&#39;s 12.3%. Shares of the company have risen 194.6% compared with the industry&#39;s 22.3% growth over the past year.&nbsp;AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.46%.
Phibro, carrying a Zacks Rank of 2 at present, has an estimated earnings growth rate of 21% for fiscal 2025 compared with the industry&#39;s 12.6%. In the past year, shares of PAHC have risen 72.7% compared with the industry&#39;s 25.2% growth. PAHC delivered a trailing four-quarter average earnings surprise of 4.10%.
<a href="https://www.zacks.com/stock/news/2345297/here-s-why-you-should-retain-brkr-stock-in-your-portfolio-now?cid=CS-BENZ-FT-analyst_blog|rank_focused-2345297">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Macro Economic Events

Mid Cap

News

Offerings

Small Cap

Economics

Markets

Analyst Ratings

Trading Ideas

AXGN

BRKR

PAHC

TMDX

Here's Why You Should Retain BRKR Stock in Your Portfolio Now

This acquisition strengthens Bruker&#39;s biophysical portfolio for the analysis of molecular interactions and kinetics, offering deeper insights into both inter-molecular and molecule-single cell interactions in drug discovery or basic research.
In FY2025, Bruker Biosensors expects additional revenues greater than&nbsp;$5 million&nbsp;from the DBS acquisition, with no material EPS impact.

Bruker Acquires Germany-Based Dynamic Biosensors GmbH; Financial Details Not Disclosed

In the last three months, 4 analysts have published ratings on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $72.5, along with a high estimate of $80.00 and a low estimate of $60.00. This current average has decreased by 9.75% from the previous average price target of $80.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1727701209_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Bruker among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$78.00</td>
<td>-</td>
</tr>
<tr>
<td>Max Masucci</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$72.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$60.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bruker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Bruker's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>All You Need to Know About Bruker</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Unraveling the Financial Story of Bruker</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Bruker showcased positive performance, achieving a revenue growth rate of 17.42% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 0.95%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.47% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Bruker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.15% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Bruker's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For Bruker

Wolfe Research analyst Doug Schenkel downgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Bruker to Peer Perform

Wells Fargo analyst Brandon Couillard initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight rating and announces Price Target of $78.

Price Target

Initiation

Wells Fargo Initiates Coverage On Bruker with Overweight Rating, Announces Price Target of $78

Asia's First 1.2 GHz NMR System Installed At Korea Basic Science Institute, Enhancing Molecular And Disease Research Capabilities

TD Cowen analyst Max Masucci maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $74 to $72.

TD Cowen Maintains Hold on Bruker, Lowers Price Target to $72

The minority investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the United States.&nbsp;

Health Care

General

Bruker Announced A Minority Investment In NovAliX, A Preclinical Contract Research Organization Specializing In Drug Discovery Services, Financial Details Of The Investment Were Not Disclosed

Guidance

Bruker Sees FY24 Adj. EPS $2.59-$2.64 vs $2.64 Est., Revenues $3.38B-$3.44B vs $3.4B Est.

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. The company reported quarterly sales of $800.700 million which beat the analyst consensus estimate of $796.541 million by 0.52 percent. This is a 17.42 percent increase over sales of $681.900 million the same period last year.

Bruker Q2 2024 Adj. EPS $0.52, Inline, Sales $800.700M Beat $796.541M Estimate

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $95 to $80.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $80

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Sell and lowers the price target from $72 to $60.

Goldman Sachs Maintains Sell on Bruker, Lowers Price Target to $60

Based on cellular biophysical markers attained using Bruker&#39;s advanced atomic force microscopy, Cellens is developing its platform for detecting bladder cancer using voided urine samples from cancer patients. The technology has shown outstanding sensitivity and specificity in pilot clinical studies.&nbsp;

Contracts

Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning

At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025944&amp;newsitemid=20240603327426&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=a41daa44ad725e00e7727bb1f19c2f3e">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the&nbsp;neofleX Imaging Profiler&nbsp;for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new&nbsp;SCiLS Scope&nbsp;software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top.
&nbsp;
&nbsp;
At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025943&amp;newsitemid=20240603348539&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=2ceaf04d6f4b7914d0d2992ddf373d95">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) launches the new top-of-the-line&nbsp;timsTOF Ultra 2&nbsp;system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new&nbsp;Spectronaut 19software and the novel PreOmics&nbsp;ENRICHplus&nbsp;kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics. Bruker is also introducing&nbsp;OmniScape&nbsp;software for top-down sequence confirmation and&nbsp;de novo&nbsp;sequencing for intact, undigested proteoforms, dissociated in the mass spectrometer.

Bruker Launches NeofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications, TimsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares are trading lower by 6.6% to $67.80 during Thursday&#8217;s session after the company announced a public offering of 6 million shares of its <a href="https://www.benzinga.com/pressreleases/24/05/b39076707/bruker-announces-pricing-of-public-offering-of-common-stock">common stock</a>.
The offering comes with an option for underwriters to purchase an additional 900,000 shares within 30 days. The offering is set to close around May 31, pending customary conditions. The proceeds will be used to reduce debt from recent strategic acquisitions, including repaying part of its revolving credit agreement. 
BofA Securities and J.P. Morgan are managing the offering, and the shares will be available on the Nasdaq Global Select Market and other venues at prevailing or negotiated prices.
See Also: <a href="https://www.benzinga.com/markets/equities/24/05/39085465/us-q1-economic-growth-downwardly-revised-to-1-3-consumer-spending-falters">US Q1 Economic Growth Downwardly Revised To 1.3%: Consumer Spending Falters</a>
<h2 class="wp-block-heading">Should I Sell My BRKR Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Bruker have decreased by 5.73% in the past year. An investor who bought shares of Bruker at the beginning of the year would take a loss of $5.42 per share if they sold it today. The stock has fallen 15.38% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $24.03.
Bruker shares have an all-time high of $94.27, representing 40.96% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Bruker stock currently has an RSI of 26.13, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
BRKR has a 52-week high of $94.86 and a 52-week low of $53.79.

Why Bruker (BRKR) Shares Are Falling During Thursday's Session

WIIM

Bruker shares are trading lower after the company announced a public offering of 6 million shares of its common stock.

Bruker intends to use the net proceeds from the offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024.

Reported Earlier, Bruker Prices Public Offering Of 6M Shares Of Common Stock

Bruker shares are trading lower after the company announced an underwritten registered public offering of 6 million shares of its common stock.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54022322&amp;newsitemid=20240529283091&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=ab98aa193ce98152d1081babd0957b3e">Bruker Corporation</a> ("Bruker" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bruker intends to use the net proceeds from this offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024. BofA Securities and J.P. Morgan are acting as joint underwriters and book-running managers for the offering.

Bruker Announces Public Offering Of 6M Shares Of Common Stock

AMR Update - Mid-2024

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Autolus Therapeutics (AUTL – Research Report), DaVita (DVA – Rese...

Analysts Conflicted on These Healthcare Names: Autolus Therapeutics (AUTL), DaVita (DVA) and Bruker (BRKR)

Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In

The 10 most actionable policies if Harris wins this November - Jefferies

Jefferies analyst Tycho Peterson maintained a Buy rating on Bruker (BRKR – Research Report) today and set a price target of $85.00. The company's s...

Jefferies Sticks to Its Buy Rating for Bruker (BRKR)

Goldman's 'Goldilocks' mid-cap picks that trade at reasonable valuations

Patrick B Donnelly, an analyst from Citi, reiterated the Buy rating on Bruker (BRKR – Research Report). The associated price target remains the sam...

Bruker Corporation: Strong Buy Recommendation on Sustained Demand and Strategic Growth Prospects

Voya Small Company Strategy Q2 2024 Commentary

Bruker (BRKR – Research Report) received a Hold rating and price target from Wolfe Research analyst Doug Schenkel today. The company's shares close...

Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research

Bruker acquires Dynamic Biosensors

AAON

ALGM

ALLY

AMKBY

APPF

ARCB

ARIS

ASPN

AUTL

AVGO

BMRN

BMYMP

BWMX

CDMO

CDZI

CDZIP

CELH

CGNX

CLSK

CPAY

CRWD

CSHI

CVNA

CYBR

DAVA

DISPF

DSCSY

EXLS

FSLR

GNTX

HXGBF

HXGBY

INSM

INTC

ISUNQ

LFUS

LSCC

MRVL

NBIX

NJDCY

NNDNF

NONOF

NVDA

ODFL

PANW

PATH

PCAR

PGNY

RGEN

RGLD

SAIA

SGIOF

SGIOY

SITE

SMCI

STAG

STLD

TECH

VALE

VRNS

VSEC

WING

WXIBF

WXXWY

XMTR

ZETA

Press Releases

Bruker Announces that Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany Has Been Suspended Effective Immediately

Bruker Announces Date and Time of Second Quarter 2024 Earnings Release and Webcast

Bruker Reports Second Quarter 2024 Financial Results

Bruker Announces Strategic Minority Investment in NovAliX

Bruker Announces Quarterly Dividend

Bruker Announces Successful Installation of 1.2 GHz Avance® NMR Spectrometer at the Korea Basic Science Institute (KBSI)

Bruker Corporation to Present at Upcoming Investor Conferences

Biotech

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

Financing

Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems

Bruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug Discovery

Agilent Technologies

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

Intérêt court

Bruker (NASDAQ:BRKR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL